Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 18th Annual Meeting

Rhea-AI Summary

Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, will exhibit at the American Association of Heart Failure Nurses 18th Annual Meeting from June 15-18, 2022, in Orlando, Florida. They aim to educate healthcare professionals on their blood volume technology, which reportedly reduces 30-day mortality by 82% and readmissions by 56%. Daxor has conducted over 60,000 tests across the U.S., contributing to better patient outcomes in various medical conditions, including heart failure.

Positive

• Demonstrated ability to significantly reduce 30-day mortality by 82% and readmissions by 56% with blood volume technology.
• Company has performed over 60,000 tests, enhancing performance metrics in hospitals.
• Ongoing multicenter trials supported by NIH in COVID-19 and heart failure treatment.

Negative

• None.

Oak Ridge, TN, June 13, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 18^th Annual Meeting from June 15-18^th, 2022 at the Rosen Shingle Creek Resort in Orlando, Florida. The AAHFN is a specialty organization dedicated to advancing nursing education, clinical practice, and research to improve heart failure patient outcomes.

“The AAHFN Annual Meeting is an exciting opportunity to generate awareness and educate nurses and other health professionals interested in heart failure how use of our blood volume technology to guide heart failure treatment has been proven to not only reduce heart failure 30-day mortality by 82% and 30-day readmissions by 56%, but also how safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms can be used to guide individualized therapy in a broad range of cardiovascular conditions,” said Kathryn Kornafel, VP of Marketing and Commercial Development.

The company will be exhibiting at Booth 212.

Register for the event here: https://www.aahfn.org/mpage/am2022.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

What is Daxor Corporation showcasing at the AAHFN 2022?

Daxor Corporation is showcasing its blood volume measurement technology, which has been shown to improve heart failure treatment outcomes.

When is the AAHFN Annual Meeting taking place?

The AAHFN Annual Meeting is taking place from June 15-18, 2022, in Orlando, Florida.

How does Daxor's technology impact heart failure treatment?

Daxor's blood volume technology reportedly reduces 30-day mortality by 82% and readmissions by 56% in heart failure patients.

How many tests has Daxor performed?

Daxor has performed over 60,000 tests at leading hospitals across the United States.